Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma / 대한내과학회지
Korean Journal of Medicine
;
: 152-158, 2019.
Artículo
en Coreano
| WPRIM
| ID: wpr-759927
ABSTRACT
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Organización y Administración
/
United States Food and Drug Administration
/
Linfocitos B
/
Receptores de Antígenos
/
Linfocitos T
/
Biomarcadores
/
Linfoma de Células B
/
Linfoma de Células B Grandes Difuso
/
Tratamiento Basado en Trasplante de Células y Tejidos
/
Corea (Geográfico)
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS